anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas. A facial sheet mask (skin repair dressing, Panion \& BF Biotech Inc, Zhuhai, China) was used to clean the face after laser treatment, and the face was cooled by air cooler for 10 minutes. The patients received three treatment sessions with a 6-week interval between each session.
The objectives of this study are three-fold. First, we would like to learn and compare the doses of radiation received by the tumor and the normal tissues in anal cancer patients treated with IMRT, and in those treated with conventional radiotherapy. Second, we wish to compare the acute effects of radiation treatment in both groups of patients. Our third objective is to evaluate the late effects of radiation treatment in both groups of patients. The first two objectives will be studied using a retrospective analysis of patients with anal cancer treated at Stanford University Medical Center. The third objective will require these patients to complete and return three quality of life questionnaires.
PURPOSE: To obtain a cephem compd. which is useful as an antibiotic by producing a cephalosporin amino substance by using a triaryl halogen phosphite complex, acylating the cephalosporin amino substance, and then deesterifying.  
     CONSTITUTION: First, a triaryl halogen phosphite complex expressed by formula I (wherein X is Cl, Br; Z is H, a 1 to 4 C alkyl, etc.) is used to obtain a compd. expressed by formula II (wherein R is H or a carboxylic acid protecting group). The compd. expressed by formula II or its salt is subjected to acylation and then to deesterification to obtain the objective 7-(D-2-phenyl-2- aminoacetoamide)-3-chloro-3-cephem-4-carboxylic acid. As for the method to obtain the compd. expressed by formula II from the compd. expressed by formula I, the method described below or the like is preferable. Namely, the compd. expressed by formula I as a halogenating agent is allowed to react with 6- or 7-acrylaminocephalosporin in the presence of a tertiary amine base in an anhydrous inert org. solvent, and then the product is allowed to react with a 1 to 15 C aliphatic alcohol in the presence of hydrogen chloride. 
     COPYRIGHT: (C)1992,JPO
Baicalin is a flavone glycoside derived from flowering plants belonging to the Scutellaria genus. Previous studies have reported baicalin's anti-inflammatory and neuroprotective properties in rodent models, indicating the potential of baicalin in neuropsychiatric disorders where alterations in numerous processes are observed. However, the extent of baicalin's therapeutic effects remains undetermined in a human cell model, more specifically, neuronal cells to mimic the brain environment in vitro. As a proof of concept, we treated C8-B4 cells (murine cell model) with three different doses of baicalin (0.1, 1 and 5 μM) and vehicle control (DMSO) for 24 h after liposaccharide-induced inflammation and measured the levels of TNF-α in the medium by ELISA. NT2-N cells (human neuronal-like cell model) underwent identical baicalin treatment, followed by RNA extraction, genome-wide mRNA expression profiles and gene set enrichment analysis (GSEA). We also performed neurite outgrowth assays and mitochondrial flux bioanalysis (Seahorse) in NT2-N cells. We found that in C8-B4 cells, baicalin at ≥ 1 μM exhibited anti-inflammatory effects, lowering TNF-α levels in the cell culture media. In NT2-N cells, baicalin positively affected neurite outgrowth and transcriptionally up-regulated genes in the tricarboxylic acid cycle and the glycolysis pathway. Similarly, Seahorse analysis showed increased oxygen consumption rate in baicalin-treated NT2-N cells, an indicator of enhanced mitochondrial function. Together, our findings have confirmed the neuroprotective and mitochondria enhancing effects of baicalin in human-neuronal like cells. Given the increased prominence of mitochondrial mechanisms in diverse neuropsychiatric disorders and the paucity of mitochondrial therapeutics, this suggests the potential therapeutic application of baicalin in human neuropsychiatric disorders where these processes are altered.
Eye-drops administered once daily for 14-21 days. There are up to two planned dose levels. The first dose level will be defined in the SAD-part of the study.
FIELD: medicine, surgery. SUBSTANCE: invention relates to use of ozone in surgery. Method involves intraarterial administration of ozonized physiological solution as an antiseptic. Topical treatment with ozonized physiological solution is carried out for two stages. At the first stage suppurative-necrotic tissues are removed by jet under pressure in outlet 80 atm. At the second stage tissues are infiltrated by jet under pressure in outlet 150 atm. In part case, intraarterial administration of ozonized physiological solution is carried out in therapeutic dose up to 5 times per 24 h, treatment course is 15 days. EFFECT: decreased amount of pelvic limb amputations, decreased level. 2 cl, 1 ex
Patients are randomised intra-operatively to either Prevena or standard dressings as long as inclusion criteria are met, and no exclusion criteria met. This is left in-situ for 7 days, unless clinically indicated.
Participants received BSC plus physician's choice chemotherapy. Chemotherapy comprises of one of the following: paclitaxel at a dose of 80 milligram per meter square (mg/m\^2) on Days 1, 8, and 15 of a 4-week treatment cycle until confirmed progressive disease or unacceptable toxicity OR irinotecan at a dose of 150 mg/m\^2 on Days 1 and 15 of a 4-week treatment cycle until confirmed progressive disease or unacceptable toxicity. Participants who are not deemed eligible to receive paclitaxel or irinotecan at the dose and schedule specified above receive BSC alone once every 3 weeks. BSC is defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and is based on investigator's discretion.
This will be a double-blind, randomized, and placebo-controlled study. At least 80 evaluable patients who are scheduled for gastrectomy for gastric adenocarcinoma cancer will be randomly assigned to the control or treatment group. Each group will have at least 40 patients. The CT scan will be evaluated before surgery and on postoperative day (POD) 90. Moreover, the patient will wear the smart watch to record daily walking steps. Laboratory data will be check before gastrectomy and on POD 90.
The present invention provides a method for determining protein kinase C-ß (PKC-ß) activity in a sample. In particular, the method of the invention detects the interaction of a PKC-ß with a substrate peptide derived from myosin heavy chain IIA that comprises a PKC-ß phosphorylation site. In one embodiment, the method comprises determining the level of phosphorylation of the substrate peptide using an antibody that specifically binds to the peptide following phosphorylation by PKC-ß. Alternatively, the method comprises determining the level of phosphate incorporated into the peptide by a PKC-ß. Also provided is a method for diagnosing a disorder associated with aberrant PKC-ß activity and a method for determining a compound that modulates PKC-ß activity. The present invention additionally provides a method for modulating PKC-ß activity using a peptide inhibitor. Peptides are also provided that are useful in the performance of the methods of invention.
The present invention discloses drug double benefitting liver medicinal granule for treating liver diseases and intestinal endotoxemia. On the basis of a theory of the intestinal endotoxemia of the generation and the development of hepatitis, the drug double benefitting liver medicinal granule is triturated in a traditional medicine square shape. The present invention is an originated drug at home and abroad. Danshen root and rhubarb are used as raw material and are decocted in water to be deposited with alcohol. The supernatant liquid of the decocted liquid is taken to be concentrated into thick paste which is made into instant granule. The present invention is researched and handpicked to be prepared by large numbers of animal experiment. In clinical, the intestinal endotoxemia is obviously lightened, and simultaneously, liver functions are remarkably improved. Thus, the drug double benefitting liver medicinal granule for treating liver diseases and intestinal endotoxemia can treat both manifestation and root cause of diseases, and curative effect is conspicuous.
Participants in the experimental group will receive 8 weeks home exercise program using a virtual reality (VR) and telerehabilitation system. The intensity and choice of game for the home program will be determined by the therapist based on the patient's abilities, interests, motivation and fatigue. The patient's performance for the VR home program will be monitored asynchronously and synchronously and the program adapted to ensure it remains at an appropriate level for the patient.
The efficacy of sertraline hydrochloride as a treatment for major depressive disorder was established in two placebo-controlled studies in adult outpatients meeting DSM-III criteria for major depressive disorder. Study 1 was an 8-week study with flexible dosing of sertraline hydrochloride in a range of 50 to 200 mg/day; the mean dose for completers was 145 mg/day. Study 2 was a 6-week fixed-dose study, including sertraline hydrochloride doses of 50, 100, and 200 mg/day. Overall, these studies demonstrated sertraline hydrochloride to be superior to placebo on the Hamilton Depression Rating Scale and the Clinical Global Impression Severity and Improvement scales. Study 2 was not readily interpretable regarding a dose response relationship for effectiveness.

Study 3 involved depressed outpatients who had responded by the end of an initial 8-week open treatment phase on sertraline hydrochloride 50–200 mg/day. These patients (N=295) were randomized to continuation for 44 weeks on double-blind sertraline hydrochloride 50–200 mg/day or placebo. A statistically significantly lower relapse rate was observed for patients taking sertraline hydrochloride compared to those on placebo. The mean dose for completers was 70 mg/day.

Analyses for gender effects on outcome did not suggest any differential responsiveness on the basis of sex.
The invention discloses a novel method for screening liver-protecting traditional Chinese medicines based on computational pharmacology. The method comprises the following steps: firstly, collecting chemical components of traditional Chinese medicine with liver protection effect, constructing a traditional Chinese medicine-liver protection component relation network according to traditional Chinese medicine-component relation data recorded in a traditional Chinese medicine database, and analyzing and identifying traditional Chinese medicine rich in liver protection components through network connectivity. Secondly, collecting traditional Chinese medicines with liver protection effect and liver toxic and side effects, taking the drug properties of the two traditional Chinese medicines as input, and constructing a drug property characteristic clustering model based on a hierarchical clustering method. Thirdly, evaluating whether the traditional Chinese medicine rich in the liver-protecting components found in the first step is closer to the liver-protecting traditional Chinese medicine in the aspect of the drug property characteristics based on the drug property characteristic clustering model. And fourthly, the traditional Chinese medicine is rich in liver protection components, is close to the traditional Chinese medicine for protecting the liver in medicinal property characteristics, is considered to have the liver protection function, and the document verification shows that the method provided by the invention has higher reliability. The method has important application value for screening new liver-protecting traditional Chinese medicines and discovering new functions of the traditional Chinese medicines.
On Cycle 1, Day 1 of the Efficacy Expansion Phase and during all subsequent cycles, participants with PD-1/PD-L1 refractory melanoma receive quavonlimab at DL1 according to Schedule 2 for up to 24 months on study. Participants who demonstrate radiographically confirmed progressive disease in Arm G will be eligible to receive combination therapy with pembrolizumab (crossover).
There is only one group of patients. Thus there is only one arm. Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. A numeric photograph of the wound will be taken at week 0, week 4 and week 12.
For the study arm A, to evaluate circadian rhythm of itching, patients will record for 7 days 6 times daily in a booklet the itch intensity on a visual analog scale (VAS) scale. These time points for itch intensity recording will be hours after time of awakening (AW), so they will be AW+2h, AW+4h, AW+6h, AW+8h, AW+10h, AW+12h. Patients are to document all their pruritus attacks at these time points. On day 8 the investigators will collect suction blisters (4-5 10mm blisters) at these 6 time points from unaffected skin on the trunk. For this purpose, the investigators will use the commercially available 47mm orifice plate (Electronic Diversities, Finksburg MD, USA) with 4-5 x10mm openings for each time point and use the 4-5 1mm blister roofs for harvesting.
The associations of dynapenic abdominal obesity and transitions with frailty progression remain unclear among middle-aged and older adults. We included 6937 participants from the China Health and Retirement Longitudinal Study (CHARLS) and 3735 from the English Longitudinal Study of Aging (ELSA). Participants were divided into non-dynapenia and non-abdominal obesity (ND/NAO), abdominal obesity alone (AO), dynapenia alone (D), and dynapenic abdominal obesity (D/AO). Frailty status was assessed by the frailty index (FI), and a linear mixed-effect model was employed to analyze the associations of D, AO, D/AO, and transitions with frailty progression. Participants with AO, D, and D/AO had increased FI progression compared with ND/NAO in both cohorts. D/AO possessed the greatest additional annual FI increase of 0.383 (95% CI: 0.152 to 0.614), followed by D and AO in the CHARLS. Participants with D in the ELSA had the greatest magnitude of accelerated FI progression. Participants who transitioned from ND/NAO to D and from AO to D/AO presented accelerated FI progression in the CHARLS and ELSA. In conclusion, dynapenic abdominal obesity, especially for D/AO and D, presented accelerated frailty progression. Our findings highlighted the essential intervention targets of dynapenia and abdominal obesity for the prevention of frailty progression.
The present invention relates to a medicated wine for treating rheumatalgia and wind diseases and a preparing method thereof, which belongs to the technical field of medicines. The medicated wine solves the problem that rheumatalgia and wind diseases can not be cured after being treated for a long time. The present invention has the scheme that notopterygium root, radix angelicae pubescentis, ledebouriella root, chuanxiong rhizome, angelica dahurica, cortex acanthopanax radices, pawpaw, radix achyranthis bidentatae, fructus aurantii, fructus psoraleae, atractylodes, atractylodes macrocephala, safflower, lithospermum erythrorhizon and cortex moutan radices are used as raw materials for preparing the medicament; the raw materials are mixed, pulverized, soaked in white spirits, filtered and deslagged so as to prepare the medicated wine. The medicated wine of the present invention has a formula formed according to disease causes, multiple medicinal smells and comprehensive effects, and warm drugs are mainly used in the formula of the medicated wine; the medicated wine has the main functions of dispelling coldness, removing dampness, realizing compatibility, removing the wind, dredging channels, activating blood circulation, nourishing blood and yin, offering warmth with moderation, and eliminating dampness without doing damage to yin; the drug property of the medicated wine moves and penetrates through wine power so as to reach the limb joints and the channels and collaterals of the whole body, and the medicated wine also has the action of realizing reinforcement and elimination in combination and carrying out two-way regulation. Clinical observation indicates that the medicated wine has the characteristics of precise curative effects and treatment of both symptoms and root causes, and the effective rate can reach 98%. Additionally, the present invention also has the advantages of rich medicinal source, simple manufacture, low cost and convenient administration.
The invention mainly relates to a formulation of a soft capsule for resisting oxidation and delaying senility and a method for preparing the soft capsule. The soft capsule for resisting oxidation and delaying senility is mainly characterized in that the soft capsule comprises the following raw materials in portion by weight: 350 to 450 weight portions of siritch, 15 to 35 weight portions of astragalus root, 15 to 20 weight portions of cervus elaphus linnaeus, and 0.8 to 2 weight portions of lycopene. The method uses a traditional Chinese medicine theory as basis, uses a research result of traditional Chinese medicine modernization as support, elaborately selects materials, and has a precise formulation, so that the formulation has the characteristics of consideration of symptom and root cause and unified coordination; the soft capsule aims at three-high symptoms universally occurring in modern people and a plurality of situations of accelerating the senility caused by environmental pollution; and natural animal and plant materials are selected, so the soft capsule can wholly condition physical metabolism and balance, improve living quality, resist oxidation and remove free radicals to achieve the aim of prolonging life. In the formulation, the astragalus root and notoginseng can improve the function of heart; the astragalus root can strengthen the contractibility of the heart; the notoginseng strengthens the dilation capacity of the heart; and two materials are matched and bring out the best in each other. For the balance between yin and yang, rhizoma polygonati is used for nourishing the yin. The compatiability of the notoginseng, propolis and the siritch has the functions of obviously improving the three-high symptoms, softening blood vessels, protecting the heart, and the like.
UV irradiation of the human skin downregulates lipid synthesis and adipokine production in subcutaneous fat. Recent evidence has suggested that UV exposure limits body weight gain in mouse models of obesity. However, the relationship between norepinephrine and UV irradiation has not been previously reported. Chronic UV exposure stimulated food intake but prevented body weight gain. Leptin, an appetite-suppressing hormone, was significantly reduced in the serum of the UV-irradiated mice. In contrast, UV irradiation induced browning of subcutaneous white adipose tissues without increasing physical activity. Notably, UV irradiation significantly increased norepinephrine levels, and the inhibition of norepinephrine production reversed the effects of chronic UV irradiation on food intake and body weight gain. In conclusion, chronic UV irradiation induces norepinephrine release, resulting in the stimulation of food intake due to the downregulation of leptin levels, but it prevents weight gain by inducing the browning process and elevating energy expenditure.
The study is a randomized, parallel group, controlled trial of two mobile app digital therapies. The study will consist of initial screening tests and diagnostics to determine eligibility, followed by outcome measure testing and treatment. On Day 0, the Baseline visit will occur wherein the pre-treatment (baseline) assessments will be conducted on-site. The Treatment period (Day 1 to Day 49) will involve using the digital therapy at home. Midpoint (Day 25) assessments will be conducted on-site to assess key outcomes. Final Post-Treatment (Day 50) assessments will be conducted on-site to assess key outcomes.
Daily use of the intervention Flexible footwear (Moleca®) for 6 months, for at least 42 hours/week (approximately 6 hours/day, 7 days/week). The Moleca® shoe (Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a low-cost women's double canvas, flexible, flat, walking shoe without heels, with a 5-mm anti-slip rubber sole and a 3-mm flat insole of ethylene vinyl acetate that provides only protection but no correction. The mean weight of the shoe is 0.172±0.019 kg (range 0.091 to 0.182 kg), depending on size. This minimalist footwear is commonly worn by the elderly of all social classes and its average cost is US$ 6.25.
The following pharmacokinetic information and conclusions were obtained from published studies that used nonspecific assay methods.

Distribution: The mean volume of distribution of glycopyrrolate was estimated to be 0.42 + 0.22 L/kg.

Metabolism: The in vivo metabolism of glycopyrrolate in humans has not been studied.

Excretion: The mean clearance and mean T1/2 values were reported to be 0.54 +0.14 L/kg/hr and 0.83+0.13 hr, respectively post IV administration. After IV administration of a 0.2 mg radiolabeled glycopyrrolate, 85% of dose recovered was recovered in urine 48 hours post dose and some of radioactivity was also recovered in bile. After IM administration of glycopyrrolate to adults, the mean T1/2 value is reported to be between 0.55 to 1.25 hrs. Over 80% of IM dose administered was recovered in urine and the bile as unchanged drug and half the IM dose is excreted within 3 hrs. 

The following table summarizes the mean and standard deviation of pharmacokinetic parameters from a study.
PROBLEM TO BE SOLVED: To stabilize (poly)alkylene glycols in a composition by adding a ultraviolet absorbing agent and/or an ultraviolet scattering agent to the composition containing the (poly)alkylene glycols. SOLUTION: There is employed a composition containing a (poly)alkylene glycol compound selected from alkylene glycols, polyalkylene glycols and derivatives thereof. As UV absorbing agents can be employed those compound used as UV absorbing agents for skin-care, and UV absorbing agents as additives to plastics or the like. As UV scattering agents, UV scattering agents for skin-care are preferable. The amount of the UV absorbing agents and/or UV scattering agents added is preferably 0.001-10% based on the total composition. More preferably, the pH of the composition containing the (poly)alkylene glycols is adjusted to 6-11.